Recon: Zevra prices newly approved Neimann-Pick disease drug at $106k per month; Novo faces Senate committee grilling over weight loss drug prices
ReconJason Scott
BiotechnologyEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyReimbursementUnited States